The prevalence of cardiovascular disease risk factors on diabetic human immunodeficiency virus-infected individuals on antiretroviral treatment : a systematic review and meta-analysis protocol

dc.contributor.authorMaswanganyi, Khanyisa
dc.contributor.authorSedibe, Amogelang
dc.contributor.authorMzimela, Nomusa C.
dc.contributor.authorGamede, Mlindeli
dc.contributor.emailu19167572@tuks.co.za
dc.date.accessioned2026-03-17T08:06:20Z
dc.date.available2026-03-17T08:06:20Z
dc.date.issued2025-09
dc.descriptionDATA AVAILABILITY STATEMENT : Data sharing is not applicable to this article as no new data were created or analyzed in this study.
dc.description.abstractBACKGROUND AND AIMS : People with human immunodeficiency virus (PLWHIV) have a higher prevalence of non-communicable diseases (NCDs) such as obesity, diabetes mellitus and cardiovascular diseases (CVDs). Previous studies have depicted that PLWHIV have these NCDs due to the predisposing risk factors of CVDs including dyslipidaemia, impaired fasting glucose, hypertension, obesity, and elevated glycated hemoglobin. Understanding the cumulative consequences of these disorders is critical in this population. Hence, the aim of this protocol is to narrate the methods and techniques that will be used to perform a systematic review and meta-analysis of the prevalence of various CVD risk factors among diabetic individuals receiving antiretroviral therapy. Furthermore, this review will explore the extent to which traditional and HIV-specific risk factors contribute to the beginning and progression of CVD in the HIV-positive population by merging available data. METHODS : Literature search will be conducted using selected keywords on databases such as PubMed, Google Scholar, Scopus, and Web of science to identify eligible publications according to the eligibility criteria. Preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines will be used for reporting and risk of bias will be assessed using the Cochrane Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I tool). Data synthesis and sensitivity analysis will be performed using RevMan software and strength of evidence will be assessed using the grading of recommendations assessment, development, and evaluation approach (GRADE) pro tool. ETHICAL CONSIDERATIONS AND REGISTRATION : This systematic review protocol is registered with PROSPERO (CRD42024524396) and it doesn't require any ethical clearance as it will use data from published reports.
dc.description.departmentPhysiology
dc.description.librarianam2026
dc.description.sdgSDG-03: Good health and well-being
dc.description.sponsorshipSupported by the South African National Research Foundation (NRF).
dc.description.urihttps://onlinelibrary.wiley.com/journal/23988835
dc.identifier.citationMaswanganyi, K., Sedibe, A., Mzimela, N.C. et al. 2025, 'The prevalence of cardiovascular disease risk factors on diabetic human immunodeficiency virus-infected individuals on antiretroviral treatment', Health Science Reports, vol. 8, no. 9, art. e71274, pp. 1-5. https://doi.org/10.1002/hsr2.71274.
dc.identifier.issn2398-8835 (online)
dc.identifier.other10.1002/hsr2.71274
dc.identifier.urihttp://hdl.handle.net/2263/109028
dc.language.isoen
dc.publisherWiley
dc.rights© 2025 The Author(s). This is an open access article under the terms of the Creative Commons Attribution‐Non Commercial‐No Derivs License,.
dc.subjectAntiretroviral therapy (ART)
dc.subjectDyslipidaemia
dc.subjectGlycated hemoglobin
dc.subjectHypercholesterolemia
dc.subjectHypertension
dc.subjectHypertriglyceridemia
dc.subjectImpaired fasting glucose
dc.subjectAntiretroviral drugs (ARVs)
dc.subjectT2DM
dc.subjectPeople living with HIV (PLHIV)
dc.subjectNon-communicable diseases (NCDs)
dc.subjectObesity
dc.subjectDiabetes mellitus
dc.subjectCardiovascular disease (CVD)
dc.subjectHuman immunodeficiency virus (HIV)
dc.titleThe prevalence of cardiovascular disease risk factors on diabetic human immunodeficiency virus-infected individuals on antiretroviral treatment : a systematic review and meta-analysis protocol
dc.typeArticle

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Maswanganyi_Prevalence_2025.pdf
Size:
255.6 KB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Maswanganyi_PrevalenceSuppl_2025.docx
Size:
73.74 KB
Format:
Microsoft Word XML
Description:
Supplementary Material

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: